



ASX Announcement

Change of Company Secretary

SYDNEY Australia Tuesday, 25 January 2022 – Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) wishes to advise in accordance with ASX Listing Rule 3.16.1 that Gillian Nairn has notified the Board of her resignation as a Company Secretary of the Company with effect from 31 January 2022.

Ms Nairn was appointed Company Secretary on 4 February 2020 ahead of the Company's listing on the ASX. Atomo thanks Ms Nairn for her support during the Company's formative stages as an ASX listed company.

The Company advises that Mr Tharun Kupppanda has been appointed as Company Secretary with effect from 25 January 2022. For the purposes of ASX Listing Rule 12.6, Mr Mr Kupppanda will also be the primary person responsible for communications between the Company and the ASX.

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement has been authorised for release by the Company's Board of Directors.

About Atomo

Atomo Diagnostics Limited is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com.